Biocon Ltd secures European Commission marketing authorization for pertuzumab biosimilar Pebrilzo®
- Authorized in the EU for HER2-positive breast cancer across multiple disease stages.
- First biosimilar approved under the EMA’s new tailored clinical approach.
- Follows recent U.S. FDA approval and adds to Biocon’s oncology biosimilar portfolio.
